Genmab — November 2022
-
royalty term from Darzalex Faspro's first commercial sale date. Harrison views Genmab's risk/reward as favorable into the 2023 ruling.
-
Okay, thanks for the clarification EL. Looks quite promissing then. But but but…
-
23xAnalytiker target og revenue forecast 2023 fra tradingview https://nbg1.your-objectstorage.com/proinvestor-dev/forum/boards/108171_Skaermbillede_2022_11_29_150015_trading_view.jpg
-
Are Investors Undervaluing Genmab A/S (CPH:GMAB) By 46%?
Today we will run through one way of estimating the intrinsic value of Genmab A/S ( CPH:GMAB ) by taking the expected...
(simplywall.st)
-
November 29, 2022 04:25 PM Eastern Standard Time
DUBLIN--(BUSINESS WIRE)--The Board of Horizon Therapeutics plc (Nasdaq: HZNP) (“Horizon” or the “Company”) confirms that it is engaged in highly preliminary discussions with Amgen Inc., Janssen Global Services, LLC and Sanofi (each a "Possible Offeror") which may or may not lead to an offer being made for the entire share capital of the Company. There can be no certainty that any offer will be made for the Company. -
Godmorgen.
-
Godmorgen.
-
Horizon bekræfter opkøbsinteresse fra Amgen, Janssen og Sanofi https://medwatch.dk/Medicinal___Biotek/article14640736.ece?utm_campaign=MedWatch Morgen&utm_content=2022-11-30&utm_medium=email&utm_source=medwatch
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind